A paradigmatic example might be silencing of the erythroid-restricted enhancer of BCL11A, which has been proposed as a therapeutic target to reawaken fetal globin expression in patients affected by β-thalassemia or sickle cell disease (Canver et al., 2015, Vierstra et al., 2015). This evidence concerns the gene BCL11A and sickle cell disease.